Thyrocare Technologies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹271 Cr +24.9% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
TT

Thyrocare Technologies Ltd

Q3 FY26Healthcare Services

Thyrocare Technologies Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹196Cr
+18.1% YoY
−9.7% QoQ
Net profit
₹28Cr
+47.4% YoY
−41.7% QoQ
Margin
30%
+5 pp YoY
−3 pp QoQ
Price₹566
Market cap₹9.5K Cr
P/E52.8

The short version

Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business. Organic growth of 15-16% over the next 2 years is achievable but will come at a cost; margins expected to remain stable, not improve significantly.

From Thyrocare Technologies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business.
  • The partnerships business is anticipated to grow about 1.5 times faster than the franchise business, contributing to consolidated mid-teens growth.
  • The company aims to maintain growth above market rates by strategic investments in franchisee network expansion and specialty offerings.
  • Specialty segments like allergies and genomics are key areas of investment for future growth and market expansion.
  • International business (e.g., Tanzania) is growing rapidly, doubling annually, though it remains a small part currently.

2 more points from Thyrocare Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company plans a field expansion with 40 new field personnel expected in the next financial year.
  • There are ongoing investments in specialty offerings, including setting up specialty labs and expanding the internal sales and doctor network (currently 80 doctors on staff).
  • Capex so far this financial year is approximately INR 20-30 crores, excluding ROU (Right of Use) asset capitalization.
  • ROU asset capitalization related to reagent rental machines increased to around INR 22-23 crores this year from INR 13 crores last year.
  • Strategy on capex remains unchanged: buy equipment where cost-effective and use reagent rental models where advantageous, e.g., biochemistry on reagent rental, immunoassay machines bought.

2 more points from Thyrocare Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Thyrocare Technologies Ltd Q3 FY26 results — key figures

Thyrocare Technologies Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue196166+18.1%217-9.7%
Operating profit (EBITDA)5842+38.1%71-18.3%
Operating margin30%25%+5 pp33%-3 pp
Profit before tax3528+25%63-44.4%
Net profit (PAT)2819+47.4%48-41.7%
EPS (₹)1.821.20+51.7%3.02-39.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q3 FY26)

    FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —

  • Aster DM Quality (Q3 FY26)

    Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…

  • Chandan Healthca (Q3 FY26)

    The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…

  • Rainbow Childrens Medicare (Q3 FY26)

    Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q3 FY26 results?

Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business. Organic growth of 15-16% over the next 2 years is achievable but will come at a cost; margins expected to remain stable, not improve significantly.

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

The company plans a field expansion with 40 new field personnel expected in the next financial year.

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.